• Chunqing Lin
  • Jiri Slama
  • Paula Gonzalez
  • Marc T. Goodman
  • Ningshao Xia
  • Aimee R. Kreimer
  • Ting Wu
  • Nancy A. Hessol
  • Yurii Shvetsov
  • Ana P. Ortiz
  • Beatriz Grinsztejn
  • Anna-Barbara Moscicki
  • Isabelle Heard
  • Maria del Refugio Gonzalez Losa
  • Erna M. Kojic
  • Maarten F. Schim van der Loeff
  • Feixue Wei
  • Adhemar Longatto-Filho
  • Zizipho A. Mbulawa
  • Joel M. Palefsky
  • Annette H. Sohn
  • Brenda Y. Hernandez
  • Katina Robison
  • Steve Simpson
  • Lois J. Conley
  • Alexandra de Pokomandy
  • Racheal S. Dube Mandishora
  • Lays P. B. Volpini
  • Alessandra Pierangeli
  • Byron Romero
  • Timothy Wilkin
  • Silvia Franceschi
  • Carmen Hidalgo-Tenorio
  • Reshmie A. Ramautarsing
  • Ina U. Park
  • Fernanda K. Tso
  • Sheela Godbole
  • Kathleen W. M. D'Hauwers
  • Borek Sehnal
  • Lynette J. Menezes
  • Sandra A. Heraclio
  • Gary M. Clifford

Background Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer.

Methods We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL.

Findings Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16.5, 95% CI 14.2-19.2, p

Interpretation HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women. Copyright Copyright (C) 2019 International Agency for Research on Cancer; licensee Elsevier.

Originele taal-2Engels
TijdschriftLancet Infectious Diseases
Nummer van het tijdschrift8
Pagina's (van-tot)880-891
Aantal pagina's12
StatusGepubliceerd - 2019

ID: 3013814